Company / Operating Margin
Ovid Therapeutics Inc. Operating Margin History
FY2022-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Margin
-10933.8%
FY2025
5-year range
-15122.7% / 59.6%
FY2022-FY2025
Trend
+27.7%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Operating Margin returned to growth in FY2025 after 2 years of decline, reaching -10933.8%.
Based on SEC 10-K filings.
-10933.8% in FY2025 with a 3-year CAGR of -10993.4%.
Declined from -3696.4% to -10933.8% over the past 2 years.
Operating Margin over time
Growth rates
- 3-Year Change
- -10993.4pp
- 5-Year Change
- -
- 10-Year Change
- -
Key checks
Key Insights
- In FY2025, operating margin increased 27.7% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.61 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -10933.8% | +27.7% |
| FY2024 | -15122.7% | -309.1% |
| FY2023 | -3696.4% | -6301.0% |
| FY2022 | 59.6% | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026